Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463256 | 1.00 | MGLL (0.46) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1463255 | 1.00 | MGLL (0.46) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1559296 | 0.91 | PTGES (0.43) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL13483727 | 0.91 | CYP2C9 (0.47) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL1463181 | 0.89 | HCRTR1 (0.51) | PTGESHCRTR1HCRTR2SCDPROKR1 | |
| SCHEMBL1463183 | 0.89 | HCRTR1 (0.51) | PTGESHCRTR1HCRTR2SCDPROKR1 | |
| SCHEMBL1463185 | 0.89 | HCRTR1 (0.51) | PTGESHCRTR1HCRTR2SCDPROKR1 | |
| SCHEMBL1462250 | 0.88 | MGLL (0.49) | MGLLHCRTR1HCRTR2CTSLCTSS | |
| SCHEMBL1462249 | 0.88 | MGLL (0.49) | MGLLHCRTR1HCRTR2CTSLCTSS | |
| SCHEMBL1462246 | 0.88 | MGLL (0.49) | MGLLHCRTR1HCRTR2CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | claimed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | MGLL 3064/4885CYP2C9 1958/4885CYP2C19 1027/4885 |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | MGLL 3064/4885CYP2C9 1958/4885CYP2C19 1027/4885 |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | MGLL 3064/4885CYP2C9 1958/4885CYP2C19 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.